ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Oxaliplatin

Also written as “oxaliplatin”, “Oxaliplatin (SR96669)” and “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”.

Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Rectal Neoplasms · Carcinoma, Hepatocellular, led by 9 companies.

Drug pageOxaliplatin: every studyMany companies study it; this page follows only the 66 they lead. All 854 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 10, 200566 company-led studies, 2 open or runningNext primary completion: Mar 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only360 open or runningphase 4since Aug 10, 2005Jan 6, 2001none ahead
Hoffmann-La Rocheits history only201 open or runningphase 4since Dec 18, 2007Sep 15, 2003Mar 22, 2027phase 1 · NCT06624085
Prologue Research Internationalits history only30 open or runningphase 3since Jun 5, 2003May 6, 2001none ahead
Pfizer21 open or runningphase 3since Oct 5, 2020Nov 6, 2007none ahead
Criteriumits history only10 open or runningphase 2since Sep 24, 2019Sep 24, 2019none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since Sep 27, 2007Sep 27, 2007none ahead
Nang Kuang Pharmaceuticalits history only10 open or runningphase 2since Mar 28, 2011Mar 28, 2011none ahead
NovoCureits history only10 open or runningno phasesince Feb 20, 2020Feb 20, 2020none ahead
Sirtex Medicalits history only10 open or runningphase 3since Aug 13, 2008Aug 13, 2008none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, Parexel, Halozyme Therapeutics, BioLineRx, AbbVie, Zai Lab, Amgen, Bristol-Myers Squibb, Regeneron Pharmaceuticals and Yakult Honsha.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 6, 2007First study: phase 1 study in Stomach NeoplasmsFirst studyNCT00555620 · 76 enrolled · Korea, Republic of
  2. Oct 5, 2020Phase 3 study in NeoplasmsNCT04607421 · 841 enrolled · United States, Argentina, Australia and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04607421Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMar 1, 2025841
NCT00555620Stomach Neoplasms · Korea, Republic of1CompletedAug 201076

How it is read

Names in the registry

  • “Oxaliplatin”, 51 entries
  • “oxaliplatin”, 20 entries
  • “Oxaliplatin (SR96669)”, 3 entries
  • “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
  • “OXALIPLATIN”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.